AnaCardio
anacardio.com
Actively hiring
Biologics & Biosimilars
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
News
KD Ventures AB旗下 portfolio公司Anacardio的候选药物AC01临床研究成果刊发于柳叶刀
AnaCardioKD Ventures AB旗下投资组合公司的全球首创类新药AC01近期在针对射血分数降低型心力衰竭HFrEF的适应症临床试验中完成第一阶段研发此前该药已顺利完成1b期临床试验关键进展与数据：获美国FDA授...
Read more
Report
AnaCardio射血分数降低型心力衰竭患者1b/2a期GOAL-HF1研究成果刊发于柳叶刀
临床阶段生物制药公司AnaCardio宣布其针对首创口服钙增敏收缩剂AC01开展的GOAL-HF1 1b/2a期临床研究结果已正式发表于柳叶刀该研究面向射血分数降低的心力衰竭HFrEF患者开展目前全球尚无安全的改善心脏收缩功能...
Read more
Report
AnaCardios Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
Favourable safety profile in marked contrast to traditional inotropic therapeuticsAC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 - AnaCardio, a clinical stage biopharmaceut
Read more
Report
AnaCardios Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 - AnaCardio, a clinical stage biopharmaceu
Read more
Report
AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF at Late-Breaking Session at HFA 2026
STOCKHOLM, Sweden, May 11, 2026 - AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), presented in a Late-Breaking Science session at the Eur
Read more
Report
AnaCardio's AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress
STOCKHOLM, Sweden, March 26, 2026 - AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have been selected for presentation in the Late-Breaking Scie
Read more
Report
AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s
Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Healthcare SA ("Helsinn"), a global pharmaceutical group
Read more
Report
AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b
December 10, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announces strong topline results from the Phase 2a portion of its GOAL-HF1 clinical study program eva
Read more
Report
AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025
Stockholm, Sweden, September 16, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejectio
Read more
Report
AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Philipp Mathieu as Chief Financia
Read more
Report
Show more news